gmp
gmp

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AKS-452

            Therapeutic Area: Infections and Infectious Diseases Product Name: AKS-452

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Akston Biosciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration September 01, 2020

            Details:

            TRACER will will provide regulatory services, oversight of local manufacturing contractors as well as Phase 1 Study preparation and clinical site management for Akston Biosciences' Phase 1 clinical testing in of its lead COVID-19 vaccine candidate, AKS-452.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): HP163

            Therapeutic Area: Infections and Infectious Diseases Product Name: HP163

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 20, 2020

            Details:

            A recent publication in Nature Neuroscience reported that Hercules’ AhR inhibitor HP163 reduces viral replication in animals infected with Zika-virus and reduced microencephaly.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): K-NK-ID101

            Therapeutic Area: Infections and Infectious Diseases Product Name: K-NK-ID101

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration August 17, 2020

            Details:

            The collaboration will study NK-cell biology in COVID-19 patients, the elimination of SARS-CoV-2 virus and virally infected cells by K-NK cells, and synergies between monoclonal antibodies, vaccines and K-NK cells.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 14, 2020

            Details:

            Saillant Therapeutics has discovered an innovative groundbreaking generic virus-inhibiting treatment platform based on activation of a cellular master regulator.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TR-C 19

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 15, 2020

            Details:

            VSY Biotechnology Research Center has developed a strong R&D program in various areas of biotechnology and is now proud to announce its latest achievement: TR-C 19, a drug to treat COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sonlicromanol

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 15, 2020

            Details:

            Company’s lead asset sonlicromanol may have potential as a repurposed treatment for PGE2-driven inflammatory consequences underlying severe COVID-19 disease.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): COVID-19 vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: University of Queensland

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership April 09, 2020

            Details:

            The UQ team will partner with the Dutch company, Viroclinics Xplore, on the crucial pre-clinical studies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): VSV∆G-SARS-CoV-2

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: IAVI

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration March 05, 2020

            Details:

            By working with Batavia Biosciences, IAVI intends to develop an end-to-end platform for flexible, low-cost production of epidemic preparedness vaccines, including vaccines against a group of viruses that cause hemorrhagic fevers and other emerging viral disease threats.